Croda International (LSE:CRDA) reported a return to healthy organic growth on 5 November, led by its beauty ingredients, and that matters more than usual for income investors. The speciality chemicals group has lifted its Dividend for 27 straight years, one of the longest such runs in the FTSE 100, yet the latest Payout Ratio shows how far Earnings have fallen behind. A sustained recovery is what would make that record look secure again.

The income numbers

As of 7 October 2026, Croda's annual dividend was 111.0p per share, with the latest payment at 48.0p. The trailing 12-month Yield is 3.4% and the indicated yield is 3.3%. Dividend growth over the past year was just 0.9%, a token increase that kept the sequence alive without pretending that all was well.

The group has paid dividends for 42 consecutive years and raised them for 27 years in succession. Only a small number of London-listed companies can match that second figure. A board with such a record will usually go to some lengths to protect it, but a long history does not guarantee the next rise, particularly when cash and earnings are under pressure.

A payout ratio that demands attention

The trailing payout ratio of 194.6% means the dividend is covered only about 0.5 times by reported earnings. In other words, Croda has been paying out nearly twice what it earned on the statutory measure over the past 12 months. Statutory earnings can be weighed down by one-off items and restructuring costs, so the ratio probably overstates the underlying strain, but it nevertheless indicates that the payout has run well ahead of profits.

A ratio at this level is not sustainable if it persists. The dividend can be maintained for a time from the balance sheet, but earnings need to recover for it to be comfortably funded. That is why the slim 0.9% rise looks like a sensible compromise, preserving the streak while limiting the cost.

Dividend cover is worth understanding in two ways. Statutory cover uses reported profit after all charges, including restructuring and impairments, while adjusted cover strips out items the company regards as non-recurring. The two can diverge widely in a year of heavy change, and readers should keep both in mind rather than relying on a single trailing number.

Beauty leads the recovery

The third-quarter update offers some of the evidence that investors have been seeking. Group sales for the three months to 30 September were about £450m, with Organic Sales growth of 6.6%. Consumer Care drove the performance, and both Beauty Actives and Beauty Care delivered double-digit percentage growth.

Croda is a supplier of specialised ingredients, mostly to makers of cosmetics, personal care products, pharmaceuticals, crop protection and industrial goods. Its customers typically destock when they are cautious and rebuild inventory when confidence returns, which is why the Business can swing between weak and healthy volumes without any change in end-demand. A rebound in Beauty therefore suggests that customer ordering patterns are normalising.

Croda also said it remains on track to deliver its outlook for 2026 and its financial framework for 2028, which includes around £100m of total annualised pre-tax benefits and a Working Capital reduction of around £50m. It expects further incremental cost savings in the second half of 2026 and during 2027. Those self-help measures matter because they should feed directly into profits, and in turn into dividend cover.

Why the streak is hard to break

For a company that has raised its dividend every year for more than a quarter of a century, the annual increase takes on symbolic weight. Boards in this position often prefer a very small increase to a pause, because a pause ends the record and invites questions about confidence. The cost of a token rise is low, since a 0.9% increase on a dividend of this size amounts to only a modest sum in absolute terms.

The difficulty is that token increases cannot continue indefinitely if earnings do not recover. For Croda (LSE:CRDA), rebuilding cover means either profits climbing back towards their previous levels or the dividend growth rate staying subdued for several years. Cost savings, a recovery in volumes and lower working capital all help, and each is part of the plan the company has laid out. The Balance Sheet provides a buffer, but it is not a substitute for earnings.

What to watch

Full-year results early next year will be the key test, showing whether adjusted operating profit reaches the level the company is guiding towards. Investors will watch for dividend cover to start rebuilding, and for any increase that goes beyond a token amount. Evidence that Demand in Beauty is continuing, and that the pharma business is contributing, would strengthen the case that the streak can extend to a 28th year.

It will also be worth tracking how cash generation develops. Working capital reductions release cash, which supports the dividend even when statutory profit is subdued. Progress on that front, alongside the cost savings the group has outlined, will tell holders of Croda (LSE:CRDA) how much of the dividend is being funded from operations rather than reserves, and whether the long record rests on a recovering business or on the board's determination to protect it.

Another point to follow is the relationship between yield and the underlying business. A yield of around 3.3% is respectable for a global speciality chemicals company, but it is the product of a declining earnings base as much as a payout choice. If profits recover, the same dividend will look more comfortably covered without any need for the board to act, which is the cleanest route back to a conventional payout ratio and a normal pace of annual increases. Readers should also remember that earnings forecasts can change quickly in a business that is sensitive to customer inventory cycles.